Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Jedd D. Wolchok" Clear advanced filters

  • The US Food and Drug Administration (FDA) recently approved the immunotherapy agents sipuleucel-T and ipilimumab for the treatment of metastatic prostate cancer and melanoma, respectively. This Opinion article discusses how immunotherapy might be improved by understanding the mechanisms that are responsible for clinical benefit, identifying biomarkers that predict response or toxicity and developing combination therapies.

    • Padmanee Sharma
    • Klaus Wagner
    • James P. Allison
    Reviews
    Nature Reviews Cancer
    Volume: 11, P: 805-812

  • Five papers extend the list of cancers that respond to therapies that restore antitumour immunity by blocking the PD-1 pathway, and characterize those patients who respond best. See Letters p.558, p.563, p.568, p.572 & p.577

    • Jedd D. Wolchok
    • Timothy A. Chan
    News & Views
    Nature
    Volume: 515, P: 496-498

  • A cancer vaccine is streamlined by identifying a small set of potent immunogens in a tumor cDNA library.

    • Francesca Avogadri
    • Jedd D Wolchok
    News & Views
    Nature Biotechnology
    Volume: 30, P: 328-329

  • The aim of immunotherapy is to treat cancer by enabling the immune system to attack the tumour. In the past decade, remarkable results have been obtained in clinical trials with immunotherapy for patients with advanced-stage cancer. Two types of immunotherapy have been used in the majority of trials conducted in the past decade: immune cell-targeted antibody therapy and adoptive cellular therapy. Herein, the latest advances in both modalities are discussed, including settings for which testing combination strategies and 'armoured' CAR T cells are recommended.

    • Danny N. Khalil
    • Eric L. Smith
    • Jedd D. Wolchok
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 13, P: 273-290

  • Targeting the immune system in tumour cells has become a central therapy for cancer treatment, but such drugs can lead to adverse effects. In this Review, the authors describe the immune-related endocrinopathies, such as hypophysitis, thyroid dysfunction and the development of diabetes mellitus that can result from cancer immunotherapy.

    • David J. Byun
    • Jedd D. Wolchok
    • Monica Girotra
    Reviews
    Nature Reviews Endocrinology
    Volume: 13, P: 195-207

  • The development of therapeutic antibodies requires a substantial understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies required to develop antibody therapies for cancer patients.

    • Andrew M. Scott
    • Jedd D. Wolchok
    • Lloyd J. Old
    Reviews
    Nature Reviews Cancer
    Volume: 12, P: 278-287